HL156A

HL156A
Clinical data
Other names	IM156, HL271 acetate, UNII-4G3BUV6ZSK
Identifiers
	IUPAC name N'-[N'-[4-(trifluoromethoxy)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide;
CAS Number	1422365-93-2;
PubChem CID	71512108;
ChemSpider	92169512;
UNII	4G3BUV6ZSK;
CompTox Dashboard (EPA)	DTXSID501336867 ;
Chemical and physical data
Formula	C13H16F3N5O
Molar mass	315.300 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCN(C1)C(=NC(=NC2=CC=C(C=C2)OC(F)(F)F)N)N;
	InChI InChI=1S/C13H16F3N5O/c14-13(15,16)22-10-5-3-9(4-6-10)19-11(17)20-12(18)21-7-1-2-8-21/h3-6H,1-2,7-8H2,(H4,17,18,19,20); Key:NGFUHJWVBKTNOE-UHFFFAOYSA-N;

HL156A is an experimental drug being studied for its potential use in cancer treatment. Chemically, it is derivative of metformin and a potent oxidative phosphorylation inhibitor and AMP-activated protein kinase activating biguanide.^[1]^[2] Certain types of cancer cells requires oxidative phosphorylation to survive. By targeting it, HL156A might help in improving anticancer therapy.^[3] It is more potent than acadesine or metformin at activating AMP-activated protein kinase.^[2] It is being developed by Hanall Biopharma.^[4]